Clinical trial
Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic…
NCT00451048 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00451048 |
|---|---|
| Title | Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia |
| Official title | A Phase II Study of Sunitinib Malate (Sutent®; SU11248) in Patients With Intermediate-2 or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | sunitinib malate |
| Enrollment | 10 |
| Start date | Feb 1, 2007 |
| Primary completion | Sep 1, 2011 |
| Completion | Oct 1, 2012 |
| First posted | Mar 22, 2007 |
| Last update posted | Sep 4, 2018 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: